GWLL on OTC
GOLDENWELL BIOTECH, INC.
GOLDENWELL BIOTECH, INC. is an American Food and Kindred Products company based in Solon, listed on OTC (GWLL).1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Steakholder Foods Ltd., Tradewinds Universal or Next Meats Holdings, Inc., or pick any stock.
- TickerGWLL on OTC1
- IndustryFood and Kindred Products1
- HeadquartersSolon, Ohio1
- Incorporated inNV2
- Business address7316 Capilano Dr., Solon, Oh 441392
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
Goldenwell Biotech, Inc. was incorporated on August 20, 2019. Our fiscal year end is December 31, and we have no subsidiaries. Our business offices are currently located at 7316 Capilano Dr., Solon, Ohio 44139. We do not conduction operations and only receive mail at such location.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$43
- Interest99¢$8.4K
Financial statements
Every line of the income statement as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | $55 | $139 |
| Service Revenue | $0 | |
| COST OF REVENUES | -$43 | -$75 |
| GROSS PROFIT | $12 | $64 |
| General and administrative | -$113.3K | -$123.2K |
| Total operating expenses | -$113.3K | -$123.2K |
| Operation Income | -$113.3K | -$123.1K |
| Interest Expense | -$8.4K | -$8.4K |
| Loss from Inventory Impairment | -$174.7K | |
| Income tax provision | $0 | $0 |
| NET LOSS | -$296.5K | -$131.5K |
| Earning per share - basic and diluted | $0.00 | $0.00 |
| Weighted average number of shares outstanding - basic and diluted | 99.0M shares | 99.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | $55 | $0 |
| Service Revenue | $0 | |
| COST OF REVENUES | -$43 | $0 |
| GROSS PROFIT | $12 | $0 |
| General and administrative | -$22.9K | -$25.4K |
| Total operating expenses | -$22.9K | -$25.4K |
| Operation Income | -$22.9K | -$25.4K |
| Interest Expense | -$2.1K | -$2.1K |
| Loss from Inventory Impairment | -$174.7K | |
| Income tax provision | $0 | $0 |
| NET LOSS | -$199.7K | -$27.5K |
| Earning per share - basic and diluted | $0.00 | $0.00 |
| Weighted average number of shares outstanding - basic and diluted | 99.0M shares | 99.0M shares |
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 9 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Cash | $26.8K | $49.4K | |||
| Inventory (related party transaction) | $174.7K | $174.8K | |||
| Less Allowance for Inventory Obsolescence | -$174.7K | ||||
| Prepaid OTCQB Fee | $9.3K | ||||
| Right of Use Assets | $0 | $0 | |||
| TOTAL ASSETS | $36.1K | $224.2K | |||
| Accounts Payable | $0 | $0 | |||
| Lease Liability | $0 | $0 | |||
| Unearned Sales Revenue | $1.9K | $1.9K | |||
| Unearned Service Revenue | $100.0K | ||||
| Accrued Legal Fee | $0 | ||||
| Total Current Liabilities | $101.9K | $1.9K | |||
| Due from the related party | $95.6K | $95.6K | |||
| Long-term liabilities | $189.2K | $189.2K | |||
| Less Discount on Long-term Liabilities | -$6.9K | -$15.3K | |||
| TOTAL LIABILITIES | $379.8K | $271.4K | |||
| Common stock, $0.0001 par value, 300,000,000 shares authorized,99,000,000 issued and outstanding at December 31, 2024 99,000,000 issued and outstanding at December 31, 2025 | $9.9K | $9.9K | |||
| Additional paid-in capital | $1.3M | $1.3M | |||
| Retained earnings | -$1.7M | -$1.4M | |||
| Total stockholders' equity | -$343.7K | -$144.0K | -$116.1K | -$85.8K | -$47.2K |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $36.1K | $224.2K | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |||
| Common stock, shares issued | 99.0M shares | 99.0M shares | |||
| Common stock, shares outstanding | 99.0M shares | 99.0M shares |
| Period ending | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | $26.8K | $49.4K | $53.2K | ||||||
| Inventory (related party transaction) | $174.7K | $174.8K | |||||||
| Less Allowance for Inventory Obsolescence | -$174.7K | ||||||||
| Prepaid OTCQB Fee | $9.3K | ||||||||
| Right of Use Assets | $0 | $0 | |||||||
| TOTAL ASSETS | $36.1K | $224.2K | |||||||
| Accounts Payable | $0 | $0 | |||||||
| Lease Liability | $0 | $0 | |||||||
| Unearned Sales Revenue | $1.9K | $1.9K | |||||||
| Unearned Service Revenue | $100.0K | ||||||||
| Accrued Legal Fee | $0 | ||||||||
| Total Current Liabilities | $101.9K | $1.9K | |||||||
| Due from the related party | $95.6K | $95.6K | |||||||
| Long-term liabilities | $189.2K | $189.2K | |||||||
| Less Discount on Long-term Liabilities | -$6.9K | -$15.3K | |||||||
| TOTAL LIABILITIES | $379.8K | $271.4K | |||||||
| Common stock, $0.0001 par value, 300,000,000 shares authorized,99,000,000 issued and outstanding at December 31, 2024 99,000,000 issued and outstanding at December 31, 2025 | $9.9K | $9.9K | |||||||
| Additional paid-in capital | $1.3M | $1.3M | |||||||
| Retained earnings | -$1.7M | -$1.4M | |||||||
| Total stockholders' equity | -$343.7K | -$144.0K | -$116.1K | -$85.8K | -$47.2K | -$20.9K | $3.4K | $53.3K | $84.3K |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $36.1K | $224.2K | |||||||
| Common stock, par value | $0.00 | $0.00 | |||||||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |||||||
| Common stock, shares issued | 99.0M shares | 99.0M shares | |||||||
| Common stock, shares outstanding | 99.0M shares | 99.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$296.5K | -$131.5K |
| Non-cash interest expense | $8.4K | $8.4K |
| Change in inventory | $43 | $75 |
| Change in Allowance for Inventory Obsolescence | $174.7K | |
| Change in Prepaid OCTQB Fee | -$9.3K | |
| Change in Unearned Sales Revenue | -$54 | |
| Change in Unearned Service Revenue | $100.0K | |
| Net Cash used in Operating Activities | -$22.6K | -$123.1K |
| Proceeds from long-term loan | $119.2K | |
| Net Cash provided by Financing Activities | $0 | $119.2K |
| Net change in cash | -$22.6K | -$3.8K |
No quarter-by-quarter statement was filed.
Corporate structure
GOLDENWELL BIOTECH, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of GOLDENWELL BIOTECH, INC.
- Ming Zhou Filed SCHEDULE 13D on GOLDENWELL BIOTECH, INC., latest Oct 9, 2026
- James L. Wang Filed SC 13G on GOLDENWELL BIOTECH, INC., latest Oct 10, 2023
- Hua Xie Filed SC 13D on GOLDENWELL BIOTECH, INC., latest May 23, 2023
- Li Yang Filed SC 13D on GOLDENWELL BIOTECH, INC., latest May 23, 2023
- Shuang Liu Filed SC 13D on GOLDENWELL BIOTECH, INC., latest May 23, 2023
- GOLDENWELL BIOTECH, INC. Solon, Ohio
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What GOLDENWELL BIOTECH, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
Inventory
Properties, in its own words
Our officers and directors work remotely, and we have an address of 7316 Capilano Dr., Solon, Ohio 44139. We do not conduction operations and only receive mail at such location. We do not own any real estate or other physical properties.
Item 2 of the 10-K filed Jul 1, 2026.3
Leadership
Who has led GOLDENWELL BIOTECH, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
- Chief executive officerShuang Liu May 23, 2023 to May 23, 202313
Timeline
- Oct 9, 20268-K Executive or director change15
- Sep 29, 20268-K Change of auditor16
- May 27, 20268-K Earlier financial statements no longer reliable17
- Aug 19, 20258-K Change of auditor18
- Jan 23, 20258-K Change of auditor19
- Nov 15, 20248-K Change of auditor20
- May 20, 20248-K Change of auditor21
- May 23, 2023New chief executive Shuang Liu becomes CEO13
Filings
63 filings to the SEC since October 2021: 6 annual reports, 20 quarterly reports, 7 major events, 4 insider forms, 5 large holders, 21 other. The latest 20:
- Oct 9, 2026SCHEDULE 13D EDGAR
- Oct 9, 20263 EDGAR
- Oct 9, 20268-K EDGAR
- Sep 29, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Jul 1, 202610-Q EDGAR
- Jul 1, 202610-K EDGAR
- Jun 29, 202610-Q/A EDGAR
- Jun 26, 202610-Q/A EDGAR
- Jun 26, 202610-Q/A EDGAR
- May 27, 20268-K EDGAR
- May 12, 2026NT 10-Q EDGAR
- Mar 31, 2026NT 10-K EDGAR
- Dec 8, 202510-Q EDGAR
- Sep 12, 202510-Q EDGAR
- Aug 19, 20258-K EDGAR
- Aug 14, 2025NT 10-Q EDGAR
- May 27, 202510-Q EDGAR
- May 15, 202510-K EDGAR
- May 14, 2025NT 10-Q EDGAR
The 63 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
SEC filer profile
How GOLDENWELL BIOTECH, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARGOLDENWELL BIOTECH, INC.1
- CIK0001800373
- Employer ID (EIN)84-28960863
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inNevada3
- Fiscal year endsDecember 311
- Industry code (SIC)2000 Food and Kindred Products1
- SEC reviewing officeOffice of Manufacturing, Division of Corporation Finance1
- Business address7316 Capilano Dr., Solon, OH 441391
- Phone440-666-79991
- Shares outstanding99,000,000 as of Aug 11, 202611
- Public float$14.5M as of Jun 30, 20253
- AuditorMICHAEL GILLESPIE & ASSOCIATES, PLLC, Vancouver, Washington PCAOB ID 6104; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceFeb 21, 20201
- Filings85 in all: 10-Q (18), UPLOAD (10), 8-K (8), NT 10-Q (8), 10-K (6), NT 10-K (6), CORRESP (5), S-1/A (5)1
All 19 form types
10-Q/A (4), 3 (4), SC 13D (3), 10-K/A (1), 144 (1), 424B3 (1), 8-A12G (1), EFFECT (1), S-1 (1), SC 13G (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Jul 1, 2026
Quarterly report (10-Q) Aug 14, 2026
Latest 8-K (8-K) Oct 9, 2026
Risk factors and legal proceedings
Legal proceedings
There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARShuang Liu, Chief executive officer
- 14SEC EDGARHua Xie, Secretary
- 15SEC EDGARExecutive or director change
- 16SEC EDGARChange of auditor
- 17
- 18SEC EDGARChange of auditor
- 19SEC EDGARChange of auditor
- 20SEC EDGARChange of auditor
- 21SEC EDGARChange of auditor
- 22
- 23
- 24
- 25
- 26